SEATTLE, May 5, 2021 /PRNewswire/ -- CTI BioPharma
Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that
management plans to report its first quarter 2021 financial results
on Tuesday, June 1, 2021, after the
close of the U.S. financial markets. Following the announcement,
members of the management team will host a conference call and
webcast to discuss the results and provide a general corporate
update at 4:30 p.m. ET (1:30 p.m. PT).
To access the live call by phone please dial (877) 735-2860
(domestic) or (602) 563-8791 (international); the conference ID is
9343326. A live audio webcast of the event may also be accessed
through the "Investors" section of CTI's website at
www.ctibiopharma.com. A replay of the webcast will be available for
30 days following the event.
About CTI BioPharma Corp.
We are a biopharmaceutical
company focused on the acquisition, development and
commercialization of novel targeted therapies for blood-related
cancers that offer a unique benefit to patients and their
healthcare providers. We concentrate our efforts on treatments that
target blood-related cancers where there is an unmet medical need.
In particular, we are focused on evaluating pacritinib, our sole
product candidate currently in active late-stage development, for
the treatment of adult patients with myelofibrosis. In addition, we
have recently started developing pacritinib for use in hospitalized
patients with severe COVID-19, in response to the COVID-19
pandemic. We are headquartered in Seattle, Washington.
CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-report-first-quarter-2021-financial-results-on-june-1-2021-301283960.html
SOURCE CTI BioPharma Corp.